他汀类药物治疗急性呼吸窘迫综合征:随机临床试验的个体患者数据荟萃分析
该个体患者数据荟萃分析纳入截至2016年10月31日的6项随机临床试验、共1755例成人ARDS患者,比较他汀与安慰剂。结果显示他汀对28天死亡率(RR 1.03,95%CI 0.86-1.23)、无呼吸机天数(均数差0.34天,95%CI -0.68至1.36)和严重不良事件(RR 1.14,95%CI 0.84-1.53)均无显著影响。他汀组血清肌酸激酶或转氨酶升高发生率显著增加(12.1% vs 8.9%,RR 1.40,95%CI 1.07-1.83,P=0.015)。预设亚组中未发现显著的治疗-协变量交互作用。作者结论为不推荐启动他汀治疗ARDS。
要点
- 成人ARDS患者启动他汀治疗对28天死亡率无显著影响(RR 1.03,95%CI 0.86-1.23)。
- 他汀组血清肌酸激酶或转氨酶升高发生率12.1%(106/879)vs 对照组8.9%(78/876),RR 1.40(95%CI 1.07-1.83,P=0.015)。
- 无呼吸机天数均数差0.34天(95%CI -0.68至1.36),严重不良事件RR 1.14(95%CI 0.84-1.53),均无显著差异。
- 预设亚组分析未发现显著的治疗-协变量交互作用。
- 作者不推荐启动他汀类药物治疗ARDS。
适用人群与场景
- 成人急性呼吸窘迫综合征(ARDS)患者,纳入6项随机临床试验共1755例。
研究设计与关键结果
- 研究类型为个体患者数据荟萃分析,纳入截至2016年10月31日的6项随机临床试验,共1755例成人ARDS患者,比较他汀治疗与安慰剂。
- 主要结局:28天死亡率RR 1.03(95%CI 0.86-1.23),无呼吸机天数均数差0.34天(95%CI -0.68至1.36),严重不良事件RR 1.14(95%CI 0.84-1.53),均无显著影响。
- 他汀组血清肌酸激酶或转氨酶升高106/879(12.1%)vs 对照组78/876(8.9%),RR 1.40(95%CI 1.07-1.83,P=0.015),他汀组显著增加。
- 预设亚组中未发现显著的治疗-协变量交互作用。
证据类型、等级与局限
- 证据类型:随机临床试验的个体患者数据荟萃分析;使用Cochrane偏倚风险工具评估偏倚风险。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者不推荐启动他汀类药物治疗ARDS。
- 成人ARDS患者启动他汀治疗无临床获益,且血清肌酸激酶或转氨酶升高发生率增加(12.1% vs 8.9%)。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
PURPOSE: We performed an individual patient data meta-analysis to assess the possible benefits and harms of statin therapy in adults with acute respiratory distress syndrome (ARDS) and to investigate effects in specific ARDS subgroups.
METHODS: We identified randomised clinical trials up to 31 October 2016 that had investigated statin therapy versus placebo in patients with ARDS. Individual patient data from each trial were compiled. Conventional two-stage meta-analyses were performed for primary and secondary outcomes, and one-stage regression models with single treatment-covariate interactions for subgroup analyses. Risk of bias was assessed using the Cochrane Risk of Bias Tool.
RESULTS: Six trials with a total of 1755 patients were included. For the primary outcomes, there was no significant effect of statin therapy on 28-day mortality [relative risk (RR) 1.03, 95% CI 0.86-1.23], ventilator-free days (mean difference 0.34 days, 95% CI -0.68 to 1.36) or serious adverse events (RR 1.14, 95% CI 0.84-1.53). There was a significantly increased incidence of raised serum creatine kinase or transaminase levels with statin therapy (106/879; 12.1%) versus control (78/876; 8.9%) (RR 1.40, 95% CI 1.07-1.83, p = 0.015). There were no significant treatment-covariate interactions in the predefined subgroups investigated.
CONCLUSIONS: We found no clinical benefit from initiation of statin therapy in adult patients with ARDS, either overall or in predefined subgroups. While there was an increased incidence of raised serum creatine kinase and transaminase levels, there was no difference in serious adverse events among groups. Therefore, we do not recommend initiation of statin therapy for the treatment of ARDS.
参考来源
- Nagendran M, McAuley DF, Kruger PS, et al. Statin therapy for acute respiratory distress syndrome: an individual patient data meta-analysis of randomised clinical trials. Intensive Care Med. 2016. PMID: 28004129. doi:10.1007/s00134-016-4649-0
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。